Genitourinary Cancers

Genitourinary Cancers

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer.

The FDA requires a risk label on GnRH agonists that indicates the increased risk of cardiovascular disease and diabetes in prostate cancer patients.

At this year’s ASCO GU Cancers Symposium, several high-impact and potentially practice-changing abstracts were presented during the prostate cancer session.

A reduction in testosterone levels in the first year of ADT correlates with improved survival in prostate cancer patients being treated for biochemical failure.

Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.

In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.

Metastatic renal cell carcinoma patients with an elevated neutrophil-to-lymphocyte ratio at baseline had inferior outcomes compared to those with a low ratio.


Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.